Elevated basal serum tryptase concentration or mastocytosis as risk factor in Hymenoptera venom allergy;Erhöhte basale serumtryptasekonzentration oder mastozytose als risikofaktor der Hymenopterengiftallergie

Allergo Journal

Volumn 13, Issue 7, 2004, Pages 440-442

  Przybilla, Bernhard ^a   Müller, Ulrich ^b   Jarisch, Reinhart ^c   Ruëff, Franziska ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Spital Bern Ziegler   (Switzerland)

^c FAZ   (Austria)

Author keywords

Hymenoptera venom allergy; Mastocytosis; Serum tryptase

Indexed keywords

HYMENOPTERA VENOM; TRYPTASE;

ALLERGY; ANAPHYLAXIS; ENVENOMATION; HUMAN; IMMUNOTHERAPY; INSECT STING; MAST CELL; MASTOCYTOSIS; REVIEW; RISK FACTOR; SYSTEMIC DISEASE;

EID: 8344273609     PISSN: 09418849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Biedermann T, Ruëff F, Sander CA, Przybilla B. Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. Br J Dermatol 1999; 146: 1110-2
2. Bucher C, Simic P, Furrer J, Wüthrich B. Mastozytose: eine wichtige Differentialdiagnose bei anaphylaktischer Reaktion auf Hymenopterenstiche. Ein Fallbericht und eine Übersicht über Klinik, Diagnostik und aktuelle Therapie der Mastozytose. Schweiz Rundschau Medizin (PRAXIS) 2000; 89: 411-8
3. Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997; 100: 11-5
4. Golkar J, Jeffrey DB. Mastocytosis. Lancet 1997; 349: 1379-85
5. Haeberli G, Brönnimann M, Hunziker T, Müller U. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33: 1216-20
6. Ludolph-Hauser D, Ruëff F, Fries C, Schöpf P, Przybilla B. Constitutionally raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357: 361-2
7. Ludolph-Hauser D, Schöpf P, Ruëff F, Przybilla B. Okkulte kutane Mastozytose. Hautarzt 2001; 52: 390-3
8. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89: 529-35
9. Oude Elberink JNG, de Monchy JGR, Kors JW, van Doormaal JJ, Dubois AEJ. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99: 153-4
10. Przybilla B, Ruëff F, Fuchs T, Pfeiffer C, Rakoski J, Stolz W, Vieluf D. Insektengiftallergie. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie. Allergo J 2004; 13: 186-90
11. Ruëff F, Ludolph-Hauser D, Przybilla B. Erhöhte basale Serumtryptase als Risikofaktor der Insektengiftallergie. Allergo J 2003; 12: S32-8
12. Ruëff F, Przybilla B, Fuchs T, Gall H, Rakoski J, Stolz W, Vieluf D. Diagnose und Therapie der Bienen- und Wespengiftallergie. Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Imunologie. Allergo J 2000; 9: 458-72
13. Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108: 1027-32
14. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweimann B, Worobec AS. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995; 96: 2702-10